WALTHAM, Mass. – October 12, 2011 – Histogenics Corporation, a privately held regenerative medicine company, today announced the formation of its Scientific Advisory Board. Histogenics is advancing NeoCart®, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the regeneration of cartilage lesions, and VeriCart™, a three-dimensional cartilage matrix to stimulate cartilage repair in a simple, one-step procedure. [Read more...]
2011-10-12 – Histogenics Appoints Scientific Advisory Board Comprised of Regenerative Medicine Leaders
October 11, 2011
2011-09-12 – Histogenics Appoints Industry Veterans to Support NeoCart® Phase 3 Clinical Development
September 12, 2011
WALTHAM, Mass. – September 12, 2011 – Histogenics Corporation, a privately held regenerative medicine company, has appointed Michael Lewis, M.D., as Chief Medical Officer and Peter Hamilton as Vice President of Manufacturing and Production. Dr. Lewis and Mr. Hamilton bring to Histogenics significant experience within the medical device and orthopaedics fields. Histogenics is advancing NeoCartÒ, an autologous bioengineered neocartilage grown outside the body using the patient’s own cells for the repair of full thickness cartilage lesions, and VeriCart™, a cartilage matrix designed, when combined with autologous stem cells, to stimulate cartilage repair in a simple, one-step procedure at the point of damage. [Read more...]
2011-07-27 – Histogenics Reports Positive Phase 2 Data for NeoCart
July 27, 2011
Histogenics Reports Positive Phase 2 Data for NeoCart Autologous Cartilage Tissue Implant for the Treatment of Knee Cartilage Injury
–Data at Two Years Post-Op Met Primary Endpoints –
WALTHAM, Mass. – July 27, 2011 – Histogenics Corporation, a privately held regenerative medicine company, today announced the presentation of positive Phase 2 data for the NeoCart Autologous Cartilage Tissue Implant (ACTI). The prospective randomized, controlled study, which was presented by Dennis Crawford, M.D., Ph.D. at the American Orthopaedic Society for Sports Medicine (AOSSM) Annual Meeting, compared NeoCart to microfracture (MF) for knee cartilage injury treatment at two years post-operation. NeoCart is a bio-engineered neo-cartilage implant containing an autologous chondrocyte population matured in a biodegradable collagen matrix. The Phase 2 results showed that ACTI treatment using NeoCart is associated with statistically significant improvements in knee and general health outcomes scores by six months, at the primary endpoint of twelve months, and that are then sustained for at least two years, and that NeoCart had a higher proportion of therapeutic responders in comparison to MF at one and two years. In addition, the study confirmed a favorable safety profile for NeoCart. [Read more...]
2011-05-11 – Histogenics Acquires ProChon Biotech
May 11, 2011
FOR IMMEDIATE RELEASE
Contact: Patrick O’Donnell
Histogenics, Inc.
781-547-7907
podonnell@histogenics.com
HISTOGENICS ACQUIRES PROCHON BIOTECH
WALTHAM, Mass.—May 11, 2011— Histogenics Corporation, a privately held regenerative medicine company, announced today that it has acquired ProChon BioTech Ltd. in a stock-for-stock exchange. Histogenics new management team will be lead by President & CEO, Patrick O’Donnell, formerly CEO of ProChon BioTech, Ltd. Mr. O’Donnell will also participate as a member of the Board of Directors. The current investors provide for a strong investor syndicate that includes Altima Partners, Boston Millennia Partners, Foundation Medical Partners, and ProChon Holdings BV. Boston Equity Advisors, LLC served as the investment bank and was responsible for identifying and arranging the transaction. [Read more...]